 LEXINGTON, Mass., April 10, 2021 GLOBE NEWSWIRE -- Agenus NASDAQ: AGEN, an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today presented new clinical data on AGEN1181, its next-generation anti-CTLA-4 antibody, at the American Association for Cancer Research AACR Annual Meeting from April 10 - 15, 2021. 